1993
DOI: 10.1111/j.1464-410x.1993.tb00715.x
|View full text |Cite
|
Sign up to set email alerts
|

The Management of Carcinoma of the Prostate after Failed Primary Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

1995
1995
2005
2005

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…Suppression of testicular androgen, either by surgical castration or by long‐term use of a luteinizing hormone‐releasing hormone (LHRH) agonist, is the most common treatment for newly diagnosed patients with metastatic prostate cancer. However, patients who fail the first line of endocrine therapy have a poor prognosis and their median survival is measured in months 1 . Labrie et al .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Suppression of testicular androgen, either by surgical castration or by long‐term use of a luteinizing hormone‐releasing hormone (LHRH) agonist, is the most common treatment for newly diagnosed patients with metastatic prostate cancer. However, patients who fail the first line of endocrine therapy have a poor prognosis and their median survival is measured in months 1 . Labrie et al .…”
Section: Introductionmentioning
confidence: 99%
“…However, patients who fail the first line of endocrine therapy have a poor prognosis and their median survival is measured in months. 1 Labrie et al proposed a theory of adrenal androgen hypersensitivity rather than androgen resistance to explain the poor response, or the relapse after an initial response, by medical or surgical castration. 2 Since then, numerous large clinical trials have compared testicular androgen blockade with maximum androgen blockade (MAB) by adding long-term treatment of anti-androgen, such as nilutamide, flutamide or cyproterone acetate, to testicular androgen blockade.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical Trials of Adjuvant Treatment [6], Hormonal manipulation used as second-line treatment in this setting has no curative intent, and its timing remains controversial [7]. However, clinical studies of adjuvant hormonal manipulation have demonstrated sig nificant improvements in local tumour control and pro gression-free survival in patients with prostate cancer [8] and breast cancer [9], Furthermore there is an accumula-A number of clinical trials of adjuvant treatment have been conducted and the results are summarised below.…”
Section: Introductionmentioning
confidence: 99%